1 month Guggenheim Initiates Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)MarketBeat
Guggenheim initiated coverage on Rhythm Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $70.00 price objective for the company.
Nasdaq 100 · Pharmaceuticals · Science
X